Search research articles
Contact Us
Filters
Showing results (11-20 of 38) with videos related to
Page
of 4
Sort By:
International Journal for Equity in Health
|
March 1, 2026
Racial, ethnic, gender and age representation of clinical trials supporting FDA approval of cancer therapies
Mingye Zhao, Yunlin Jiang, Taihang Shao, et al.
Health Economics Review
|
April 11, 2025
Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study
Mingye Zhao, Yunlin Jiang, Taihang Shao, et al.
Frontiers in Public Health
|
March 13, 2023
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
Mingye Zhao, Taihang Shao, Zhuoyuan Chi, et al.
Health Economics Review
|
May 20, 2026
Economic evidence of alternative formulations and routes of administration for identical active pharmaceutical ingredient: a systematic review
Hanqiao Shao, Yunong Jiang, Mingye Zhao, et al.
Frontiers in Public Health
|
September 1, 2022
Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
Taihang Shao, Yinan Ren, Mingye Zhao, et al.
Medicine
|
December 20, 2023
Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing
Yunlin Jiang, Mingye Zhao, Ruolin Liu, et al.
Frontiers in Pharmacology
|
October 17, 2022
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
Mingye Zhao, Taihang Shao, Yinan Ren, et al.
BMC Public Health
|
August 11, 2023
Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China
Leyi Liang, Taihang Shao, Hao Li, et al.
International Journal of Environmental Research and Public Health
|
April 23, 2022
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
Mingye Zhao, Zhuoyuan Chi, Xingming Pan, et al.
Pharmacoeconomics - Open
|
February 9, 2023
Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
Taihang Shao, Mingye Zhao, Leyi Liang, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 38) with videos related to
Sort By:
Page
of 4
International Journal for Equity in Health
|
March 1, 2026
Racial, ethnic, gender and age representation of clinical trials supporting FDA approval of cancer therapies
Mingye Zhao, Yunlin Jiang, Taihang Shao, et al.
Health Economics Review
|
April 11, 2025
Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study
Mingye Zhao, Yunlin Jiang, Taihang Shao, et al.
Frontiers in Public Health
|
March 13, 2023
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
Mingye Zhao, Taihang Shao, Zhuoyuan Chi, et al.
Health Economics Review
|
May 20, 2026
Economic evidence of alternative formulations and routes of administration for identical active pharmaceutical ingredient: a systematic review
Hanqiao Shao, Yunong Jiang, Mingye Zhao, et al.
Frontiers in Public Health
|
September 1, 2022
Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
Taihang Shao, Yinan Ren, Mingye Zhao, et al.
Medicine
|
December 20, 2023
Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing
Yunlin Jiang, Mingye Zhao, Ruolin Liu, et al.
Frontiers in Pharmacology
|
October 17, 2022
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
Mingye Zhao, Taihang Shao, Yinan Ren, et al.
BMC Public Health
|
August 11, 2023
Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China
Leyi Liang, Taihang Shao, Hao Li, et al.
International Journal of Environmental Research and Public Health
|
April 23, 2022
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
Mingye Zhao, Zhuoyuan Chi, Xingming Pan, et al.
Pharmacoeconomics - Open
|
February 9, 2023
Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
Taihang Shao, Mingye Zhao, Leyi Liang, et al.
Page
of 4